TUCSON
HER2 companion diagnostics cleared for gastroesophageal adenocarcinoma
- Sponsor
- Roche $RHHBY
- Drug
- ZIIHERA · zanidatamab-hrii
- Indication
- HER2-positive metastatic gastroesophageal adenocarcinoma
FDA approves expanded use of Roche's PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma patients eligible for treatment with ZIIHERA.
What this means
Ziihera is an antibody drug that attaches to HER2, a protein found on certain cancer cells, to slow tumor growth. Today FDA approved two lab tests to help doctors identify patients with gastroesophageal adenocarcinoma who may benefit from Ziihera. These companion diagnostics are important because they ensure the drug is used for the specific cancer patients it was designed to treat.
Drug Watch — recent news on ZIIHERA
- Jazz Pharmaceuticals plc (JAZZ) latest stock news and headlines - uk.finance.yahoo.com
- Jazz Pharmaceuticals plc (JAZZ) latest stock news and headlines - Yahoo Finance Singapore
- Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
- Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
- JAZZ: Zanidatamab and EPIDIOLEX anchor a robust pipeline targeting oncology and epilepsy growth - tradingview.com